Symposium 9: Recent applications of physiologically-based pharmacokinetics (PB-PK) in drug discovery and development.
Tracks
Track 1
| Friday, December 12, 2025 |
| 11:00 AM - 1:00 PM |
Details
The principles of physiologically-based pharmacokinetics (PB-PK) are well established, however the application of PB-PK modelling to support effective decision making within drug discovery and development are ever-increasing. Further to this, the recent widely-publicised FDA announcement of policies heralding an anticipated end to animal testing will undoubtedly result in significant growth of PB-PK modelling under the broad umbrella of “Non-Animal Models (NAMs)”.
This symposium will present a number of very recent examples of the application of PB-PK modelling to advance the development of diverse therapeutic modalities ranging from small molecules and peptides delivered via non-traditional routes (such as the pulmonary route and lymphatics), through to mRNA, monoclonal antibodies and biologics.
Speaker
Prof Carl Kirkpatrick
Director, Centre for Medicine Use and Safety
Monash University
Presenter
Biography
Carl is Professor of Pharmacy Practice, Medicine Use and Safety. He has a significant portfolio of research in optimising pharmacotherapy via pharmacokinetic/pharmacodynamic modelling techniques to improve patient outcomes. His research interests include population pharmacokinetic and pharmacodynamic modelling, monitoring and bayesian optimisation of dosing of antibacterial agents (especially aminoglycosides), optimisation of dosing in renal dysfunction, pharmacokinetics and dosing in obesity, drugs in breast milk and quality use of medicines.
Dr Jessica Tait
Postdoctoral Research Fellow
Monash University
PB-PK modelling in support of optimising LNP-delivery of mRNA therapeutics
Biography
Miss Jia Li
PhD Student
Centre for Medicine Use and Safety, Monash University
PK-PK modelling of subcutaneously-administered Anakinra in extreme neonates
Biography
Chair
Carl Kirkpatrick
Director, Centre for Medicine Use and Safety
Monash University
Cornelia Landersdorfer
Senior Lecturer and Research Group Leader
Monash University
Dave Shackleford
Research Director
Centre for Drug Candidate Optimisation, Monash University
